Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new combination drug treatment for women with ovarian cancer that has stopped responding to other treatments.
- Platinum-resistant Ovarian Cancer
- Peritoneal Carcinoma
- Ovarian Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have received previous treatment with a specific type of medication called a WEE1 inhibitor.You have a heart condition that causes heart failure, such as problems with your heart muscle, blocked blood vessels in your heart, damage to your heart valves, high blood pressure affecting your heart, or severe congestive heart failure.You are able and willing to take medication by mouth.You have taken any experimental medication within the last 28 days.You are currently taking medications that have been linked to a heart rhythm problem called TdP (Torsades de Pointes), as listed on crediblemeds.org.You are allergic to drugs that are similar to ZN-c3 and niraparib, or to any of the ingredients in these medications.
- Group 1: ZN-c3 and Niraparib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the scope of this trial's implementation?
"Ten different study sites are currently accepting participants, such as Aurora's Site 0264, Eugene's Site 0201 and Grand Rapids' Site 0228. Several other medical centres also have open recruitment slots."
What aims are investigators of this experiment aiming to fulfill?
"The primary assessment for this 18 month long experiment is the incidence and severity of Dose Limiting Toxicities (DLTs) in DLT-evaluable subjects during Cycle 1. Secondary targets include a comprehensive review of overall survival, maximum plasma concentration of ZN-c3 and niraparib when given together, as well as an analysis on clinical benefit rate, progression free survival, and 4-month rates according to revised RECIST version 1.1 criteria."
Is this experiment accepting new participants?
"Affirmative. Clinicaltrials.gov has evidence that this research trial, which was initially posted on the 27th of January 2022, is currently looking for enrolment from 138 participants across 10 sites."
How many individuals are contributing to this research initiative?
"To carry out the trial, 138 participants that meet the enrolment criteria are necessary. The K-Group Beta sponsor will be running this study from two different designated sites: 0264 in Aurora, Colorado and 0201 in Eugene, Oregon."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger